<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-205 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-205</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-205</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-164502a687f04effb4ac5dadbdd9d806fde4264c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/164502a687f04effb4ac5dadbdd9d806fde4264c" target="_blank">Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.</a></p>
                <p><strong>Paper Venue:</strong> Journal of Clinical Oncology</p>
                <p><strong>Paper TL;DR:</strong> This study represents the first comprehensive and concurrent analysis of major recurrent oncogenic mutations found in a large cohort of lung adenocarcinomas from East Asian never-smokers and indicates that prospective mutation testing in these patients should successfully assign a targeted therapy in the majority of cases.</p>
                <p><strong>Cost:</strong> 0.011</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e205.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e205.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR (East Asian never-smokers)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor kinase domain mutations in lung adenocarcinoma from East Asian never-smokers</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Directly measured prevalence and spectrum of EGFR kinase-domain mutations in 52 resected lung adenocarcinomas from Chinese never-smokers; majority of tumors harbor classic activating EGFR mutations (exon 19 deletions and exon 21 L858R).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td>East Asian (Chinese) never-smokers with resected lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td>52</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>78.8% (41/52) overall; females 82.9% (34/41 female patients); males 63.6% (7/11 male patients); no T790M detected in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Exon 19 deletions: 21 tumors; L858R (exon 21) point mutation: 18 tumors; exon 20 insertion: 1 tumor; double mutation (exon 18 G719S + exon 21 L861Q): 1 tumor; other (non-T790M) rare variants as above. Total EGFR-mutant tumors = 41.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>The paper does not identify a molecular causal mechanism for ethnic differences but cites/notes: (1) association of never-smoking status with enrichment for EGFR mutations (lifestyle/smoking history factor); (2) observational association of East Asian ethnicity with higher EGFR mutation frequency (ethnicity effect noted in prior studies); (3) rare germline EGFR T790M variants noted in literature but not observed here; (4) co-occurrence of PIK3CA mutations and exon 20 insertions may influence drug sensitivity but are not proposed explanations for ethnic prevalence differences.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Evidence is observational: (a) This study documents very high EGFR prevalence (78.8%) in an East Asian never-smoker cohort; (b) prior retrospective studies cited in the Introduction showed enrichment of EGFR mutations among never-smokers and East Asians and corresponding higher responses to EGFR TKIs (refs cited in text, e.g., IPASS); (c) prior work showing EGFR mutation likelihood decreases with increasing pack-years (referenced as Pham et al., ref 9) supports a role for smoking exposure as a modifying factor; (d) the paper cites literature showing some mutation frequency differences by ethnicity for other genes (eg, LKB1 more frequent in Caucasians, ref 29), providing precedent for ethnic differences in somatic mutation spectra.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>This study did not perform analyses that identify causal genetic, environmental, or ancestral mechanisms for the observed ethnic enrichment; the authors explicitly state they have no mechanistic explanation in this work. No direct genetic (germline ancestry) data, environmental exposure measurements, or lifestyle quantification beyond 'never-smoker' status were collected to test causal hypotheses. Thus there is no positive mechanistic evidence within this paper disproving alternate explanations; rather, mechanistic causes remain untested here.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>High EGFR mutation prevalence implies the majority of East Asian never-smoker lung adenocarcinoma patients can be assigned targeted therapy: prospective genotyping is recommended. The paper links mutation prevalence to clinical response: prior trials cited showed higher response rates to gefitinib in EGFR-mutant patients (e.g., 71.2% response in known EGFR-mutants in IPASS vs 43% overall), and the authors estimate expected population-level response rates given the observed mutation spectrum and co-mutations/resistance-associated variants (exon 20 insertion, concurrent PIK3CA).</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Single-institution surgical series/cohort of consecutively resected lung adenocarcinomas from never-smokers; concurrent targeted mutational analysis (PCR/sequencing) for multiple oncogenes and selected tumor suppressors.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td>Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases. J Clin Oncol. 2010 Oct 20;28(30):4616-4620. doi:10.1200/JCO.2010.29.6038.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e205.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Ethnic association (East Asian vs others)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Observed higher prevalence of EGFR mutations in East Asian patients compared with non-Asian populations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites and discusses prior observations that East Asian ethnicity is associated with a higher likelihood of EGFR-mutant lung adenocarcinoma and higher response rates to EGFR TKIs compared with other ethnic groups.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>Not quantified in this paper for non-Asian groups; paper states EGFR mutations are enriched in patients with East Asian ethnicity based on prior studies and clinical trial populations (eg, IPASS enrolled East Asian patients and found higher responses among EGFR-mutant tumors).</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Same canonical activating EGFR mutations (exon 19 deletions, exon 21 L858R) are the mutations enriched in East Asian cohorts as reported in prior literature and referenced here.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>The paper reports the ethnicity association but does not propose a specific mechanistic explanation; it implies possible contributions from differing smoking prevalence/histories across populations and references literature documenting differing mutation spectra (eg, LKB1 differences), but does not ascribe causality to genetic ancestry, environmental exposures, or other factors.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Observational epidemiologic evidence from prior studies: retrospective correlations between East Asian ethnicity and higher EGFR mutation frequency and TKI response (cited in Introduction and Discussion, including IPASS). Supporting precedent that other somatic mutation frequencies differ by ethnicity (eg, LKB1 - ref 29).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>No mechanistic dissection performed in this paper; absence of direct genetic or environmental analyses means no contradictions or confirmations of proposed underlying causes are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>Because East Asian patients (and never-smokers) are enriched for EGFR mutations, trials and clinical decisions in East Asian populations benefit from routine EGFR mutation testing; ethnicity-aware screening strategies may improve targeted therapy allocation.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Discussion/summary of prior observational and clinical-trial literature; this paper's own cohort provides supporting data (high prevalence in Chinese never-smokers) but does not directly compare ethnic groups.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e205.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the prevalence, types, and mechanisms of EGFR mutations in lung cancer across different populations, especially East Asians versus others, including proposed genetic, environmental, or lifestyle explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Smoking history effect</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Inverse correlation between cigarette smoking (pack-years) and likelihood of EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Paper cites prior studies showing that EGFR mutation frequency is higher in never-smokers and decreases as pack-years of smoking increase; the current study restricted to never-smokers to examine mutation spectrum.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>population_studied</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_prevalence</strong></td>
                            <td>Within this study's never-smoker cohort: 78.8% (41/52); the paper states that prior studies have shown EGFR mutation likelihood decreases with increasing pack-years but does not provide those numeric gradients here.</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_types</strong></td>
                            <td>Classic activating EGFR mutations predominate among never-smokers (exon 19 deletions, L858R); smoking-associated mutation patterns (eg, higher KRAS) are noted in contrast but not quantified in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>Lifestyle (direct tobacco-smoke exposure) is proposed as a modifying factor influencing somatic mutation spectra: heavier smoking is associated with reduced EGFR mutation frequency and increased prevalence of other mutations (e.g., KRAS) in lung adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_mechanisms</strong></td>
                            <td>Referential epidemiologic data cited in the Introduction (Pham et al., ref 9) showing pack-years inversely correlate with EGFR exon 19/21 mutation likelihood; this study's design (restricting to never-smokers) and observed high EGFR prevalence provide correlative support.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_mechanisms</strong></td>
                            <td>No direct mechanistic demonstration in this paper (e.g., molecular pathways by which smoke exposure suppresses EGFR-mutant tumor emergence) and no quantified pack-year analyses were performed here; the paper notes shared molecular features between minimal/remote smokers and never-smokers but does not exclude other contributing factors.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_implications</strong></td>
                            <td>Smoking history can be used clinically to estimate pre-test probability of EGFR mutation and guide mutation testing or empiric therapy choices; trial selection criteria (eg, IPASS included never/light smokers) leveraged this association.</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Background/epidemiologic observation cited from prior studies; current study is a never-smoker cohort designed to remove smoking as a confounder.</td>
                        </tr>
                        <tr>
                            <td><strong>reference</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.', 'publication_date_yy_mm': '2010-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas <em>(Rating: 2)</em></li>
                <li>Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>